Rachel Narozniak, MA | Authors

Articles

Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH Mutations

March 21, 2020

Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.

Plasma Genotyping May Change Practice in NSCLC, Says Li

November 12, 2019

In a presentation describing the utility of circulating tumor DNA liquid biopsy assays at the 14th Annual New York Lung Cancers Symposium, Bob T. Li, MD, MPH, said that plasma genotyping demsonstrates practice-changing potential in non–small cell lung cancer.

Neoadjuvant Immunotherapy Holds Promise for Patients With Resectable NSCLC

November 10, 2019

According to Tina Cascone, MD, PhD, in a presentation during the 14th Annual New York Lung Cancers Symposium, neoadjuvant immunotherapy is under investigation for patients with non–small cell lung cancer and holds hope as a treatment for patients.